NEW YORK, Feb 6 (Reuters) - An artificial intelligence-driven shakeout in the heavyweight technology sector is set to keep stock investors on edge in the coming week while a barrage of data could ...
Two of the companies battered by this week’s artificial-intelligence selloff, Thomson Reuters and Intercontinental Exchange, argued Thursday their valuable troves of proprietary data will shield them ...
President Trump says tariffs have strengthened the economy, but GDP growth was actually below average during the first nine months of 2025. The S&P 500's forward price-to-earnings ratio is above 22, ...
After Disney’s (DIS) quarterly earnings release, the share price grew to $117.50 before sinking toward $100. Disney’s quarterly revenue increased 5% year over year, but the company’s operating income ...
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. 1. The S & P 500 was higher to start the new month ...
A Florida python hunter recently captured a 202-pound Burmese python, one of the heaviest on record. Although not venomous, pythons have sharp, fang-like teeth that can cause painful bites. Invasive ...
The UK government’s Department for Science, Innovation and Technology (DSIT) has completed what it calls the “discovery phase” of its bid to create a National Data Library (NDL). The NDL was trumpeted ...
Nvidia has invested $2 billion in AI infrastructure provider CoreWeave, the companies announced. Shares of CoreWeave popped on the news. Nvidia purchased CoreWeave Class A common stock at $87.20 per ...
This company was a hit during the 1990s tech boom but fell from grace in the ensuing bust in the early 2000s. Its technology remained relevant, but the stock languished for decades. Now, it has soared ...
Super Micro Computer (SMCI), a significant assembler of advanced data center computing infrastructure, has been one of the major beneficiaries of the artificial intelligence surge. However, this ...
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results